Debio 0932

1061318-81-7

C22H30N6O2S

DMSO : >= 33 mg/mL (74.56 mM)

Metabolic Enzyme/Protease; Cell Cycle/DNA Damage

Debio 0932 is an orally active HSP90 inhibitor, with IC₅₀s of 100 and 103 nM for HSP90alpha and HSP90beta, respectively. IC50 & Target: IC50: 100 nM (HSP90alpha), 103 nM (HSP90beta)^[1] In Vitro: Debio 0932 is an orally active HSP90 inhibitor, with IC₅₀s of 100 and 103 nM for HSP90alpha and HSP90beta, respectively. Debio 0932 (CUDC-305) binds to the tumor HSP90 complex with a mean IC₅₀ of 48.8 nM. Debio 0932 (1 uM) promotes degradation of multiple HSP90 client proteins in cancer cell lines. Debio 0932 also shows inhibitory activities against the proliferation of 40 cancer cell lines (containing 34 solid and 6 hematologic tumor-derived lines) with an IC₅₀ ranging from 40 to 900 nM (mean IC₅₀, 220 nM)^[1]. Debio 0932 strongly binds to cancer-derived HSP90 complex with an IC₅₀ of 61.2 nM in H1975 cells and 74.2 nM in H1993 cells, respectively. Debio 0932 (CUDC-305, 1 uM) durably induces oncoprotein degradation in NSCLC cell lines with mutations that can confer resistance to erlotinib^[3]. In Vivo: Debio 0932 (CUDC-305, 30 mg/kg, p.o.) exhibits favorable pharmacokinetic profiles in tumor-bearing nude mice. Debio 0932 (160 mg/kg, p.o.) causes degradation of HSP90 client proteins, suppresses tumor growth, and also prolongs survival in various animal models of U87MG glioblastoma. Debio 0932 (40, 80, or 160 mg/kg, p.o.) also dose-dependently inhibits tumor growth in the U87MG s.c. tumor model by every-other-day (q2d) dosing^[1]. Debio 0932 (80 mg/kg, p.o.) significantly alleviates psoriasis by day 11 and decreases epidermal thickness in psoriasis xenograft transplantation model^[2]. Debio 0932 (CUDC-305) is able to cross the blood-brain barrier. Debio 0932 (80, 120, and 160 mg/kg, p.o.) shows dose-dependent inhibition of tumor growth in the H1975 subcutaneous tumor model. Debio 0932 (160 mg/kg, p.o.) also promotes antitumor activity in the erlotinib-resistant H1975 subcutaneous tumor model^[3].